We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The International Society for Pharmaceutical Engineering has launched a drug shortage assessment and prevention tool that helps drugmakers identify risks early on. Read More
Amgen has struck a deal with Harvard Pilgrim Health Care, through which it could pay rebates if its new cholesterol drug Repatha does not perform as well as it did in clinical trials. Read More
Days after signing a diabetes deal with Sanofi for $4.2 billion, South Korean Hanmi turned around to sign another diabetes deal with Janssen Pharmaceuticals. Read More
AstraZeneca has agreed to buy San Mateo, Calif.-based ZS Pharma, a seven-year-old company whose hyperkalemia candidate ZS-9 could prove to be a blockbuster, in a deal valued at about $2.7 billion. Read More
French drugmaker Sanofi is looking to future-proof its diabetes franchise by in-licensing rights to a trio of next-generation diabetes medicines from South Korea’s Hanmi in a deal worth up to $4.2 billion. Read More
The Federal Court of Canada has quashed Health Canada’s import ban on drugs from two Apotex facilities in India, saying the agency proceeded unfairly. Read More
Mylan may move forward with its proposed hostile takeover bid of Perrigo, as long as it divests seven generic drugs, the FTC has determined. The move is the final regulatory hurdle for Mylan’s bid and eases the FTC’s concerns that the deal would harm competition. Read More